TL;DR:
- Recursion unveils Valence Labs, a machine learning research laboratory focused on cutting-edge methods for drug discovery.
- Valence Labs combines Recursion’s ML research teams and Valence Discovery team.
- The goal is to rewrite the rules of therapeutic discovery through open science and academic research.
- Valence Labs commits up to $1 million in academic-oriented initiatives, including Valence Scholarships and Valence Fellows.
- Recursion emphasizes its belief in open-science initiatives and contributing to rising talent and academic collaborations.
Main AI News:
On a momentous occasion at the International Conference on Machine Learning (ICML), Recursion, a prominent clinical stage TechBio company with a mission to decode biology for the advancement of drug discovery, introduced Valence Labs to the world. This state-of-the-art machine learning research laboratory is laser-focused on pioneering the next wave of cutting-edge methodologies and models for drug discovery. It is the result of the strategic amalgamation of Recursion’s emerging ML research teams and the esteemed Valence Discovery team, which was recently acquired by Recursion.
“With the unprecedented convergence of Recursion’s sheer scale, computational prowess, and industrialized data generation capabilities, liberated from the shackles of one-off, rate-limiting, manual experimentation, we find ourselves presented with a truly generational opportunity. Our mission is to boldly rewrite the rules of therapeutic discovery,” proclaimed Dan Cohen, President of Valence Labs. He expressed unwavering confidence in their ability to forge future-forward tools, models, and benchmarks that are destined to become the gold standard for machine learning research in the rapidly expanding techbio industry. Moreover, their commitment to open science and academic research seeks to foster a vibrant and collaborative community.
During the grand inauguration, Valence Labs made a compelling pledge to invest up to $1 million in academic-oriented initiatives, aimed at nurturing and honing talent in the domain of machine learning research. A central pillar of this endeavor involves granting Valence Scholarships, which will provide invaluable support for individuals pursuing academic research at the intersection of artificial intelligence and biology. Additionally, Valence Fellows will be handpicked from among outstanding students with a commendable history of community engagement and/or publication in the field of machine learning for drug discovery. These exceptional scholars will receive enhanced financial backing and gain privileged access to Valence Labs’ abundant resources, empowering them to further their research pursuits.
“Embracing the philosophy of open-science, Recursion is passionately invested in bolstering rising talent and promoting fruitful academic collaborations. Moreover, we remain steadfast in our legacy of contributing substantial datasets and research tools for the betterment of scientific exploration,” asserted Chris Gibson, Ph.D., Co-founder, and CEO of Recursion. He expressed immense optimism, firmly believing that Valence Labs would emerge as a beacon and a hub for the research community, attracting extraordinary talents poised to make groundbreaking discoveries and harness the power of computation to revolutionize lives.
Conclusion:
The launch of Valence Labs by Recursion represents a groundbreaking development in the field of drug discovery. By harnessing the power of machine learning and open science, Valence Labs aims to set new standards in the industry. The investment in academic-oriented initiatives and scholarships will foster collaboration and nurture talent, ensuring a continuous flow of groundbreaking discoveries. This move by Recursion not only strengthens its position in the market but also solidifies its commitment to advancing scientific research and revolutionizing the future of drug development.
